TWD
VRTX icon

True Wealth Design’s Vertex Pharmaceuticals VRTX Stock Holding History

True Wealth Design’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.9K Buy
173
+127
+276% +$56.3K 0.02% 300
2026
Q1 		$20.5K Buy
46
+34
+283% +$15.9K 0.01% 705
2025
Q4 		$5.44K Buy
12
+2
+20% +$862 ﹤0.01% 1056
2025
Q3 		$3.73K Sell
10
-18
-64% -$7.52K ﹤0.01% 1198
2025
Q2 		$12.3K Buy
28
+1
+4% +$461 ﹤0.01% 507
2025
Q1 		$12.9K Buy
27
+17
+170% +$7.92K ﹤0.01% 416
2024
Q4 		$3.83K Buy
10
+3
+43% +$1.39K ﹤0.01% 585
2024
Q3 		$3.26K Hold
7
– – ﹤0.01% 671
2024
Q2 		$3.28K Buy
7
+2
+40% +$868 ﹤0.01% 307
2024
Q1 		$2.09K Buy
5
+2
+67% +$845 ﹤0.01% 342
2023
Q4 		$1.22K Hold
3
– – ﹤0.01% 335
2023
Q3 		$1.04K Hold
3
– – ﹤0.01% 316
2023
Q2 		$1.06K Sell
3
-6
-67% -$2.02K ﹤0.01% 322
2023
Q1 		$2.84K Buy
9
+6
+200% +$1.8K ﹤0.01% 310
2022
Q4 		$866 Buy
+3
New +$914 ﹤0.01% 355

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

True Wealth Design's VRTX Position: Q2 2026 in Review

True Wealth Design increased its Vertex Pharmaceuticals (VRTX) stake by 276% in Q2 2026, buying an estimated $56.3K and bringing the position to 173 shares worth $85.9K. The position accounts for 0.02% of the portfolio, ranked #300.

True Wealth Design first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • True Wealth Design held 173 shares of Vertex Pharmaceuticals worth $85.9K as of Q2 2026.
  • True Wealth Design bought 127 Vertex Pharmaceuticals shares in Q2 2026, an estimated $56.3K.
  • Vertex Pharmaceuticals made up 0.02% of True Wealth Design's portfolio in Q2 2026, its #300 holding.
  • True Wealth Design first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.